The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model
Abstract
Familial amyloidotic polyneuropathy is an autosomal dominant disorder mainly characterized by the extracellular deposition of transthyretin, with special involvement of the peripheral nerve. Several animal models have been generated, including transgenic mice carrying the most prevalent TTR mutation (TTR Val30Met). TTR‐Val30Met mice without endogenous TTR (TTR‐Val30Met X TTR‐KO) were previously analyzed in our laboratory and ∼60% of the animals over 1 year of age were found to have deposition as amyloid, i.e., with Congo red (CR) ‐positive material, constituting a good tool to investigate the effect of drugs on TTR deposition and fibrillogenesis. We recently showed that the drug doxycycline acts in vitro as a TTR fibril disrupter. In the present work we assessed the activity of this drug in vivo in the TTR‐Met30Val X TTR‐KO mice. Doxycycline was administrated in the drinking water to 23‐to 28‐month‐old mice over a period of 3 months. Immunohistochemistry analyses revealed no differences in nonfibrillar TTR deposition between treated ( n =11) and untreated mice ( n =11). However, CR‐positive material was observed only in the control group (untreated) whereas none of the animals treated with doxycycline was CR‐positive. Immunohistochemistry for several markers associated with amyloid, such as matrix metalloproteinase‐9 (MMP‐9) and serum amyloid P component (SAP), was performed. MMP‐9 was altered with significantly lower levels in treated animals compared with the control group. Mouse SAP was absent in treated animals, being observed only in untreated animals presenting TTR congophilic deposits. These results indicate that doxycycline is capable of disrupting TTR CR‐positive amyloid deposits and decreases standard markers associated with fibrillar deposition, being a potential drug in the treatment of amyloidosis. FASEB J. 20, 234–239 (2005)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis
Pepys, M. B., Herbert, J., Hutchinson, W. L., Tennent, G. A., Lachmann, H. J., Gallimore, J. R., Lovat, L. B., Bartfai, T., Alanine, A., Hertel, C., et al. (2002) · Nature · doi:10.1038/417254a · Cited by 540
Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene
Botto, M., Hawkins, P. N., Bickerstaff, M. C. M., Herbert, J., Bygrave, A. E., Mcbride, A., Hutchinson, W. L., Tennent, G. A., Walportz, M. J., & Pepys, M. B. (1997) · Nature Medicine · doi:10.1038/nm0897-855 · Cited by 266 · cited 1×
“Furthermore, several reports indicate that although not essential in amyloid deposition, SAP significantly accelerates the reaction (26, 27 ).”
BackgroundSousa, M. M., Du Yan, S., Fernandes, R., Guimarães, A., Stern, D., & Saraiva, M. J. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-19-07576.2001 · Cited by 212
Self-citationKoistinaho, M., Malm, T. M., Kettunen, M. I., Goldsteins, G., Starckx, S., Kauppinen, R. A., Opdenakker, G., & Koistinaho, J. (2005) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600040 · Cited by 120
Cited by
Transthyretin (TTR) Cardiac Amyloidosis
Ruberg, F. L., & Berk, J. L. (2012) · Circulation · doi:10.1161/circulationaha.111.078915 · Cited by 708
Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment
Siddiqi, O. K., & Ruberg, F. L. (2018) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2017.07.004 · Cited by 333
Bemporad, F., & Chiti, F. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.02.003 · Cited by 275
Castaño, A., Drachman, B. M., Judge, D., & Maurer, M. S. (2015) · Heart Failure Reviews · doi:10.1007/s10741-014-9462-7 · Cited by 254
Emerging Therapies in Transthyretin Amyloidosis – A New Wave of Hope After Years of Stagnancy?
Müller, M. L., Butler, J., & Heidecker, B. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1695 · Cited by 74
Metadata
- Authors
- Cardoso, I., & Saraiva, M. J.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2006-02
- Volume
- 20
- Issue
- 2
- Pages
- 234-239
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W1986840808
- Cited by
- 158
- References
- 4
- FWCI
- 1.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model. https://app.cochat.ai/papers/10.1096/fj.05-4509com
- The paper
- Cardoso, I., & Saraiva, M. J. (2006). Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model. The FASEB Journal. https://doi.org/10.1096/fj.05-4509com
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.